Table 1.
Clinical characteristics, serum neurofilament light chain levels (NFL), serum contactin-1 (CNTN1) levels, and complement activation of patients with IgM anti-MAG peripheral neuropathy and IgM MGUS/WM without PN
| Patients with IgM anti-MAG PN (n = 24) |
IgM MGUS/WM patients without PN (n = 10) |
P value | |
|---|---|---|---|
| Age (years), mean (range) | 69 (55–80) | 69 (44–81) | – |
| Male, n (%) | 13 (57%) | 6 (60%) | – |
| Duration of disease (years, range) | 4.5 (0–13) | – | – |
| Underlying hematologic diagnosis | |||
| IgM MGUS | 20 (87%) | 6 (60%) | – |
| WM | 3 (13%) | 4 (40%) | – |
| Serum IgM (mg/dL) | 670 (170–2940) | 1912 (494–5514)a | – |
| Anti-MAG titer > 10.000, n (%) | 20 (95%) | – | – |
| Presence of monoclonal cells in the bone marrow (No. (%) patients) | 7 (39%)b | 5 (83%)c | – |
| Serum NfL, median (IQR) | 17.7 (15.5–26.1) | 16.6 (12.3–24.5) | 0.42 |
| Abnormal serum NfL, N (%) | 4 (17%) | 1 (10%) | N.A |
| Abnormal serum NfL level range | 29.7–42.8 | 59.2 | |
| Serum CNTN1, median (IQR) | 10,761 (9658–12,492) | 9708 (8600–12,373) | 0.38 |
| Abnormal serum CNTN1, N (%) | 1 (4%) | 1 (10%) | N.A |
| Patients with IgM anti-MAG PN (n = 19) |
Healthy controls (n = 12) |
P value | |
|---|---|---|---|
| C3b/c (mmol/L), median (IQR) | 135 (101–170) | 222 (212–227) | |
| abnormal C3b/c, N (%) | 4 (21%) | – | – |
| abnormal C3b/c level range | 256–303 | – | – |
| C4b/c (mmol/L), median (IQR) | 23.5 (16.7–33) | 20.3 (18.9–21.2) | |
| Abnormal C4b/c, N (%) | 5 (26%) | – | – |
| Abnormal C4b/c range | 36.6–64.2 | – | – |